• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Should FDA Filing Acceptance Require Action From Cogent Biosciences Stock Investors?

    Simply Wall St·09/18/2026 05:31:47
    Listen to the news
    • Cogent Biosciences reported that the FDA previously accepted its New Drug Application for bezuclastinib in advanced systemic mastocytosis, set a June 29, 2027 PDUFA date, and indicated no advisory committee or review issues at that time.
    • The NDA is based on APEX trial data, in which bezuclastinib produced a 65% overall response rate by mIWG-MRT-ECNM criteria and 81% by pure pathological response. This result refines the discussion of how this candidate could influence Cogent Biosciences' future product mix across multiple KIT-driven diseases.
    • The next step is to assess how Cogent Biosciences' investment narrative could be shaped by the FDA's clean acceptance of bezuclastinib.

    Scan how Cogent Biosciences fits into the wider biotech story by lining it up against other late stage compound developers in our curated 16 high quality undiscovered gems.

    What Is Cogent Biosciences' Investment Narrative?

    The Cogent Biosciences story is all about conviction in bezuclastinib as a platform asset. Management is effectively building the whole business around one lead therapy across three KIT driven indications. The FDA acceptance of the AdvSM NDA, with no advisory committee planned and no review issues flagged, reinforces that this program is moving on a defined regulatory clock. In the near term, the real swing factors remain the three clustered PDUFA dates in late 2026 and mid 2027 and how efficiently Cogent can gear up for commercial launch if approvals follow.

    Operationally, this is still a pre revenue biotech with reported revenue of US$0 and a net loss of US$377.2m, so burn, capital access and any further dilution matter more than near term earnings optics. Expanded Access Programs and multiple NDAs under review create real execution complexity for a company of this size. The stock has had a very strong 1 year total return of 160.9% but also saw an 11.3% decline over the past month, which shows how tightly sentiment is tied to trial data and FDA milestones.

    Even so, there is a specific pressure point in the Cogent Biosciences story that only becomes clear once you look at ...

    There's only one way to know the right time to buy, sell or hold Cogent Biosciences. Head to Simply Wall St's company report for the latest analysis of Cogent Biosciences's Fair Value.

    NasdaqGS:COGT 1-Year Stock Price Chart
    NasdaqGS:COGT 1-Year Stock Price Chart

    Reach Your Own Conclusion

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond Cogent Biosciences?

    If you want to round out your work on Cogent Biosciences with fresh opportunities, the Simply Wall St Screener can surface other stocks that fit very different risk and return profiles.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.